+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diphtheria, Pertussis, and Tetanus Vaccine Market by Product Type and by End User: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • PDF Icon

    Report

  • 193 Pages
  • May 2020
  • Region: Global
  • Allied Market Research
  • ID: 5125486
The global diphtheria, pertussis, and tetanus (DTP) vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% during the forecast period.

Diphtheria, tetanus, and pertussis or DTP, are serious diseases caused by bacteria. DTP vaccine is a blend of diphtheria and tetanus toxoids adsorbed with pertussis vaccine for intramuscular vaccination. Diphtheria and tetanus toxoids and pertussis vaccine are recommended simultaneously for successful immunization of children up to seven years of age against diphtheria, tetanus, and pertussis (whooping cough) provide an impactful boost to the market growth. Approximately 86 % of infants worldwide (116.3 million children) received 3 doses of diphtheria-tetanus-pertussis 3 (DTP3) vaccine during 2018, shielding them from infectious diseases that may cause severe illness and disability, or could even be fatal. .

In 2017, the global demand for all D&T containing vaccines was estimated at around 945 million doses. Self-procuring countries represent almost half of the global demand for DTP vaccines. The WHO has recommended a life course of six doses of diphtheria and tetanus containing vaccines throughout the world. Thus, established firms are currently devoting almost 5% of their total R&D expenditure in vaccine development. Since last decade, biotech firms have emerged as a new force in the area of early stage product development and applied vaccine research. Players operating in the DTP vaccines market are mostly focused on establishing a strong network with dealers and their distributors. Players are partnering with other vaccine manufacturing companies to enhance their product portfolio as well as to expand their global reach. Vaccine development technology has witnessed a revolutionary growth, and has led to the expansion of innovative and new diagnostic technologies with various advancements in therapeutic applications.

The report classifies the global DTP vaccines market based on products, age group, end users, and region. By product, it is categorized into a DTaP vaccine (Diphtheria-Tetanus-acellular Pertussis vaccine), TD (tetanus and diphtheria) vaccine, and Tdap (Tetanus-diphtheria-acellular Pertussis vaccine). By age group, it is divided into adult and pediatric. By End Users, it is categorized into hospitals, clinics, and vaccination centers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global DTP Vaccine market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Product Type
  • DTaP
  • TD
  • Tdap

By Age Group
  • Adult
  • Pediatric

By End User
  • Hospitals
  • Clinics
  • Vaccination Centers

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS
  • AJ Vaccines
  • Bionet-Asia
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Massbiologics
  • Meiji Holdings Co., Ltd. (KM biologics co., Ltd.)
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
Chapter 2: Executive Summary
2.1. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Player Positioning, 2019
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise in Initiatives by Pharma Companies to Enhance Vaccine R&D
3.4.1.2. Growth in Awareness Among People About the Advantages of Dtp Vaccines
3.4.2. Restraints
3.4.2.1. Inadequate Access to Vaccines in Under Developed Countries
3.4.2.2. High Cost of Vaccine Development
3.4.3. Opportunities
3.4.3.1. Innovative Vaccine Technologies
Chapter 4: Dtp Vaccines Market, by Product Type
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Dtap Vaccines
4.2.1. Key Market Trends and Opportunities
4.2.2. Market Size and Forecast
4.2.3. Market Analysis, by Country
4.3. Td Vaccines
4.3.1. Key Market Trends and Opportunities
4.3.2. Market Size and Forecast
4.3.3. Market Analysis, by Country
4.4. Tdap Vaccines
4.4.1. Key Market Trends and Opportunities
4.4.2. Market Size and Forecast
4.4.3. Market Analysis, by Country
Chapter 5: Dtp Vaccines Market, by Age Group
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Adults
5.2.1. Market Size and Forecast
5.2.2. Market Analysis, by Country
5.3. Pediatrics
5.3.1. Market Size and Forecast
5.3.2. Market Analysis, by Country
Chapter 6: Dtp Vaccines Market, by End-user
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Hospitals
6.2.1. Market Size and Forecast
6.2.2. Market Analysis, by Country
6.3. Clinics
6.3.1. Market Size and Forecast
6.3.2. Market Analysis, by Country
6.4. Vaccination Centers
6.4.1. Market Size and Forecast
6.4.2. Market Analysis, by Country
Chapter 7: Dtap Vaccines Market, by Region
7.1. Overview
7.1.1. Market Size and Forecast
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, by Product
7.2.3. Market Size and Forecast, by Age Group
7.2.4. Market Size and Forecast, by End-user
7.2.5. Market Size and Forecast, by Country
7.2.5.1. U. S. Market Size and Forecast, by Product
7.2.5.2. U. S. Market Size and Forecast, by Age Group
7.2.6. Market Size and Forecast, by End-users
7.2.6.1. Canada Market Size and Forecast, by Product
7.2.6.2. Canada Market Size and Forecast, by Age Group
7.2.7. Market Size and Forecast, by End-users
7.2.7.1. Mexico Market Size and Forecast, by Product
7.2.7.2. Mexico Market Size and Forecast, by Age Group
7.2.8. Market Size and Forecast, by End-users
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, by Product
7.3.3. Market Size and Forecast, by Age Group
7.3.4. Market Size and Forecast, by End-user
7.3.5. Market Size and Forecast, by Country
7.3.5.1. Germany Market Size and Forecast, by Product
7.3.5.2. Germany Market Size and Forecast, by Age Group
7.3.6. Market Size and Forecast, by End-users
7.3.6.1. France Market Size and Forecast, by Product
7.3.6.2. France Market Size and Forecast, by Age Group
7.3.7. Market Size and Forecast, by End-users
7.3.7.1. UK Market Size and Forecast, by Product
7.3.7.2. UK Market Size and Forecast, by Age Group
7.3.8. Market Size and Forecast, by End-users
7.3.8.1. Italy Market Size and Forecast, by Product
7.3.8.2. Italy Market Size and Forecast, by Age Group
7.3.9. Market Size and Forecast, by End-users
7.3.9.1. Rest of Europe Market Size and Forecast, by Product
7.3.9.2. Rest of Europe Market Size and Forecast, by Age Group
7.3.10. Market Size and Forecast, by End-users
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, by Product
7.4.3. Market Size and Forecast, by Age Group
7.4.4. Market Size and Forecast, by End-users
7.4.5. Market Size and Forecast, by Country
7.4.5.1. Japan Market Size and Forecast, by Product
7.4.5.2. Japan Market Size and Forecast, by Age Group
7.4.6. Market Size and Forecast, by End-users
7.4.6.1. China Market Size and Forecast, by Product
7.4.6.2. China Market Size and Forecast, by Age Group
7.4.7. Market Size and Forecast, by End-users
7.4.7.1. Australiamarket Size and Forecast, by Product
7.4.7.2. Australia Market Size and Forecast, by Age Group
7.4.8. Market Size and Forecast, by End-users
7.4.8.1. India Market Size and Forecast, by Product
7.4.8.2. India Market Size and Forecast, by Age Group
7.4.9. Market Size and Forecast, by End-users
7.4.9.1. Rest of Asia-Pacificmarket Size and Forecast, by Product
7.4.9.2. Rest of Asia-Pacific Market Size and Forecast, by Age Group
7.4.10. Market Size and Forecast, by End-users
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, by Product
7.5.3. Market Size and Forecast, by Age Group
7.5.4. Market Size and Forecast, by End-users
7.5.5. Market Size and Forecast, by Country
7.5.5.1. Brazil Market Size and Forecast, by Product
7.5.5.2. Brazil Market Size and Forecast, by Age Group
7.5.6. Market Size and Forecast, by End-users
7.5.6.1. South Africa Market Size and Forecast, by Product
7.5.6.2. South Africa Market Size and Forecast, by Age Group
7.5.7. Market Size and Forecast, by End-users
7.5.7.1. Rest of LAMEA Market Size and Forecast, by Product
7.5.7.2. Rest of LAMEA Market Size and Forecast, by Age Group
7.5.8. Market Size and Forecast, by End-user
Chapter 8: Company Profiles
8.1. Aj Vaccines
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.2. Bionet-Asia
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.3. GlaxoSmithKline plc (Gsk)
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.4. Johnson & Johnson
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Massbiologics
8.5.1. Company Overview
8.5.2. Company Snapshot1
8.5.3. Product Portfolio
8.6. Meiji Holdings Co. Ltd. (Km Biologics Co. Ltd.)
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Merck & Co. Inc.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Panacea Biotec Ltd.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves and Developments
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.9.6. Key Strategic Moves and Developments
8.10. Serum Institute of India Pvt. Ltd
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Product Portfolio

Executive Summary

According to the report titled, 'Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market by Product, Age Group, and End User: Opportunity Analysis and Industry Forecast, 2020-2027', the global Diphtheria, Tetanus, and Pertussis Vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% from 2020-2027. The DTaP segment accounted for major market share in the total DTP vaccine market in 2020.

The key factors such as rise in demand for DTaP vaccine and growth in adoption of pertussis vaccine around the globe drives the growth of DTaP segment. Furthermore, high efficacy and rise in demand in developing regions is expected to drive the market during the forecast period. In addition, introduction of new combination of vaccines with DTaP further provides opportunities for the market players.

On the basis of age group segment, the pediatric segment is expected to grow at a significant CAGR of 4.9% during the forecast period, owing to increase in obese population worldwide. Vaccines for adults are likely to show high growth potential due to rise in incidences of infectious diseases among adults. In addition, growth in research and development and strong product pipeline is also likely to increase growth of the segment during the forecast period.

By end user, in 2019, the hospitals segment dominated the DTP vaccines market, with large share due to faster availability of these vaccines in hospitals and shorter duration of procedure. Hospitals are the integral part of the healthcare sector, which act as the major source for revenue generation and aid in research and innovation.

Key Findings of the Study:

DTaP is expected to be one of the most lucrative segments, registering a CAGR of 5.0% during the forecast period.
The Pediatric segment accounted for maximum share in the global DTP vaccines market in 2019, and is expected to grow at a CAGR of 4.9% during the forecast period.
U.S. dominated the North America DTP Vaccine market, and is projected to retain this trend throughout the forecast period.
India is expected to exhibit the highest growth in the Asia-Pacific DTP Vaccine market, registering a CAGR of 6.6% during the forecast period.
South Africa is expected to witness the highest growth in the LAMEA DTP Vaccine market, growing at a CAGR of 5.5% during the forecast period.
In 2019, North America is expected to remain dominant during the forecast period due to high awareness and demand for DTaP vaccines and presence of major key players along with R&D laboratories. In addition, wide availability of advanced systems supplements the growth of the DTP vaccines market. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, owing to the increasing awareness in countries such as India and China.

The key players operating in the global DTaP vaccine market are AJ Vaccines, Bionet-Asia, GlaxoSmithKline plc (GSK), Johnson & Johnson, Massbiologics, Meiji Holdings Co., Ltd. (KM biologics co., Ltd.), Merck & Co., Inc., Panacea Biotec Ltd., Sanofi, and Serum Institute of India Pvt. Ltd.

Companies Mentioned

  • DTP Vaccine market
  • namely AJ Vaccines
  • Bionet-Asia
  • GlaxoSmithKline plc (GSK)
  • Johnson & Johnson
  • Massbiologics
  • Meiji Holdings Co. Ltd. (KM biologics co. Ltd.)
  • Merck & Co. Inc.
  • Panacea Biotec Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information